## Insight Briefs ### ICH E6(R3) Annex 2 **ICH E6(R3) Annex 2**, adopted 3 June 2026, establishes Good Clinical Practice standards for trials that use real-world data. [Learn more](/content/insight-briefs/ich-e6r3-annex2-decentralized-trials-rwd-gcp/index.html) --- ### UK clinical trial regulations reform 2026 The Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2025 (SI 2025/538) came into force on 28 April 2026. [Learn more](/content/insight-briefs/uk-clinical-trial-regulations-reform-2026/index.html) --- ### Global eConsent Country Readiness Guide 2025 Electronic consent is now approved or conditionally approved in 27 of 33 countries assessed in Castor's eConsent Country. [Learn more](/content/insight-briefs/econsent-country-readiness-guide/index.html) --- ### The 2027 RWE Playbook Most RWE programs weren't built for 2027. They were built for 2019 — before FDA issued device-specific guidance. [Learn more](/content/insight-briefs/the-2027-rwe-playbook/index.html) --- ### Trust LLMs with Chart Review: Validation Framework Most AI chart review vendors oversell accuracy and ignore the pipeline problem entirely. [Learn more](/content/insight-briefs/llm-clinical-data-extraction-validation/index.html) --- ### The eCOA Iceberg: uncovering the hidden costs of software-only models SaaS eCOA looks cheaper on paper. This guide exposes five hidden costs that change the full-service vs. software-only dynamics. [Learn more](/content/insight-briefs/ecoa-saas-vs-full-service-hidden-costs/index.html) --- ### The ePRO blueprint for pain trials: Optimizing data capture from protocol design to efficacy endpoints The 11-point electronic Numeric Rating Scale (eNRS) is now the preferred digital standard for BYOD pain trials. [Learn more](/content/insight-briefs/epro-blueprint-pain-scale-guide/index.html) --- ### Obesity RWD Compliance: The Direct-to-Patient Guide Over 2,000 active obesity and GLP-1 studies are competing for the same patients. [Learn more](/content/insight-briefs/obesity-rwd-direct-to-patient-action-plan/index.html) --- ### Own Your Data, Accelerate Your Cure Castor Catalyst — Rare Disease Insight Brief Rare disease foundations no longer need to wait for pharmaceutical industry interest to develop treatments for their communities. [Learn more](/content/insight-briefs/patient-led-drug-development-rare-disease/index.html) --- ### The real-time monitoring dilemma Offline eCOA capability creates regulatory tension with EMA device-as-source requirements. [Learn more](/content/insight-briefs/ecoa-offline-real-time-monitoring-dilemma/index.html) --- ### Is Your eCOA UAT Stuck in Time? Modern clinical trials increasingly rely on complex, time-sensitive logic within eCOA systems. [Learn more](/content/insight-briefs/ecoa-uat-time-dependent-workflows/index.html) --- ### The End of the “PRO Tax”: Top 10 Commercial PROs & their cost-effective alternatives The clinical trial industry faces a "PRO Tax"—the high costs and operational delays associated with licensing and implementing. [Learn more](/content/insight-briefs/pro-tax-top-10-commercial-pros-cost-effective-alternatives/index.html) --- ### The Silent Saboteurs: Why Rater Drift and Site Unpreparedness Cost CNS Trials More CNS trials fail not from technology limitations but organizational factors. [Learn more](/content/insight-briefs/rater-drift-site-prep-cns-ecoa-trials/index.html) --- ### Hospital-Based eCOA Implementation: Real Challenges in Infectious Disease Trials Hospital-based infectious disease trials face unique eCOA implementation challenges including IT security delays. [Learn more](/content/insight-briefs/hospital-ecoa-implementation-infectious-disease/index.html) --- ### Implications of Assessing Overall Survival in Oncology Studies The FDA’s August 2025 draft guidance reshapes oncology clinical trials. [Learn more](/content/insight-briefs/implications-assessing-overall-survival-oncology/index.html) --- ### The Patient Experience Paradox: eCOA Strategy Overhaul Discover how the EMA’s new Patient Experience Data (PED) guidance is reshaping evidence. [Learn more](/content/insight-briefs/patient-experience-data-new-ema-guidance-why-ecoa-strategies-need-overhaul-2025/index.html) --- ### Automated Evidence Generation for Regulatory-Grade Real-World Data Manual data abstraction can’t keep up with new FDA and EMA RWE standards. [Learn more](/content/insight-briefs/automated-evidence-generation-regulatory-grade-real-world-data/index.html) --- ### The EMR Interoperability Dream vs. Clinical Research Reality Discover the real-world challenges of EMR interoperability in clinical research. [Learn more](/content/insight-briefs/emr-interoperability-dream-vs-clinical-research-reality/index.html) ---